期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (3)
Background and aim: Cardiac sarcoidosis (CS) is the second most common cause of death in patients with sarcoidosis and data pertaining to its diagnosi......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (2)
The aim of this study was to evaluate if CT findings in patients with pulmonary Post Covid syndrome represent residua after acute pneumonia or if SARS......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (4)
Introduction: As little is known about the prognostic value of CT scan findings at onset in patients presenting with sarcoidosis, we aimed to identify......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (3)
Background and aim: Pulmonary artery aneurysms (PAAs) are the most well-defined type of pulmonary vascular complication in Behcet's disease (BD). The ......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (2)
Background and aim: New parameters in the 6-minute walk test (6MWT) are needed for assessing exercise capacity in patients with idiopathic pulmonary f......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (1)
Sarcoidosis is a multisystem inflammatory disease manifesting as noncaseating epithelioid cell granulomas. 25 to 30% of individuals with systemic sarc......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (3)
Background: Bleomycin causes increased production of reactive oxygen species, leads to pulmonary toxicity, fibroblast activation, and fibrosis. Object......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (4)
. Interstitial lung disease (ILD) is a common complication that can develop during the course of systemic sclerosis (SSc). Nindetanib is an antifibrot......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (4)
Background and aim: There are many epidemiological pieces of evidence that show combined pulmo-nary fibrosis and emphysema (CPFE) patients have an inc......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (2)
Background. Sarcoidosis may seriously hamper patients' quality of life despite fairly good prognosis. Objectives. To assess the relationship between t......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (4)
Background and aim: The effect of COVID-19 in patients with sarcoidosis has not been fully explored. The aim was to conduct a retrospective cohort stu......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (4)
We present a case diagnosed with hepatosplenic sarcoidosis. Elevated liver enzymes and hypercalcemia were detected in the patient admitted to the hosp......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (3)
Sarcoidosis may progress to pulmonary fibrosis in 5% of patients with significantly increased mortality. Histopathology shows fibrosis in a lymphangit......
期刊： SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023; 40 (4)
The sarcoidosis community in general and the World Association of Sarcoidosis and Other Granulomatous diseases (WASOG) in particular have led efforts ......
